A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis
Phase 2
- Conditions
- Psoriasis10014982
- Registration Number
- NL-OMON30076
- Lead Sponsor
- Synergie/ Ilse pharma consultancy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 37
Inclusion Criteria
Subject must be 18 years of older. Subject should be male or female not of childbearing potential. Subject should have a clinical diagnose of plaque psoriasis with a BSA of more then 10% and a PASI of more then 10.
Exclusion Criteria
Subject has a history of sensitivity to any of the ingredients in the study medication
Subject is currently participating in, or has within the 30 days prior to the clinical trial participated in an investigational clinical trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method